Kun for helsepersonell

Søk

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss

Menu

Close

Om ZaviceftaVirkningsmekanismePatogen dekningTidlig hensiktsmessig behandlingIDSA anbefalingØkonomiske holdepunkterSpørsmål og svar om ZAVICEFTAPasientprofilerHAP/VAP pasientcUTI pasientcIAI pasientPediatriske pasienterSpørsmål og svar - FAQsEffekt Real-world evidenceEffektdataSpørsmål og svar om effektSikkerhetSikkerhet hos voksneSikkerhet hos barn/ungdomSpørsmål og svar om sikkerhetDoseringDosering hos voksneDosering hos barn/ungdomSpørsmål og svar om dosering
Antimicrobial resistance is a growing threat, with treatment options urgently needed for patients at risk of MDR Gram-negative infections1,2Pasientprofiler Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes.2HAP/VAP patient profile*

Identifying a patient with HAP/VAP at high-risk of MDR Gram-negative infections.

Peter

68-year old male

Patient history

  • Smoker
  • Immunosuppressed
  • COPD
  • Frequent travel
  • Chronic renal insufficiency

Symptoms
Infection symptoms include:

  • Wheezing
  • Change in colour and amount of sputum
  • Leukocytosis
  • Tachypnoea
  • Cough
  • Sweating
  • New and increasing fever
Diagnosis

COPD exacerbation requiring ventilation; 4 days later, developed VAP

Suspected pathogens
  • MDR Gram-negative pathogens, including K. pneumoniae, E. coli, P. aeruginosa
  • Based on patient’s disease severity, there is concern about potential involvement of carbapenem-resistant strains
Patient risk factors for a MDR 
Gram-negative infection Listen to Professor Jean-François Timsit

Head of the Medical and Infectious Disease ICU, AP-HP Bichat Claude Bernard Hospital, Université de Paris as he explores treatment considerations for the HAP/VAP patient.

Why ZAVICEFTA is an appropriate choice for your HAP/VAP patients ZAVICEFTA: As effective as a carbapenem in hospitalised patients with Gram-negative HAP, including VAP.12Explore more
Infectious Thinking

Listen to episode 5 of our ‘Infectious Thinking’ podcast on severe CRE HAP patients and CPE.

LoadingHAP/VAP

Discover more about HAP/VAP in a clinical setting.

Loading
Prescribing information

View ZAVICEFTA prescribing information.

Loading
Footnotes:*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA (ceftazidime–avibactam) could be considered.
†Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and does not inhibit many class D enzymes.8
§To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.8Abbreviations:COPD, chronic obstructive pulmonary disease; CRE, carbapenem-resistant Enterobacterales; ESBL, extended spectrum beta-lactamase; HAP, hospital-acquired pneumonia; ICU, intensive care unit; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase VAP, ventilator-associated pneumonia.References:Timsit J-F, et al. Intensive Care Med 2019; 45:573–91.Bonine NG, et al. Am J Med Sci 2019;357:102–10.Bassetti M, et al. Exp Rev Anti Infect Ther 2017;15:55–65.Miller BM, et al. Am J Infect Control 2016;44:134–7.De Waele J, et al. Intensive Care Med 2018;44:189–96.Albur M, et al. Ann Clin Microbiol Antimicrob 2016;15:23.
Harris AD, et al. Emerg Infect Dis 2007;13:1144–9.
ZAVICEFTA. Summary of Product Characteristics, 2022.
Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71.
Zhanel GG, et al. Drugs 2013;73:159–77.
Mazuski JE, et al. Surg Infect 2017;18:1–76.
Torres A, et al. Lancet Infect Dis 2018;18:285–95.
Carmeli Y, et al. Lancet Infect Dis 2016;16:661–73.
Mazuski JE, et al. Clin Infect Dis 2016;62:1380–9.
Wagenlehner FM, et al. Clin Infect Dis 2016;63:754–62.
Pasientprofiler
Preparatomtale
PP-ZVA-NOR-0141 Mai 2023

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei